Skip to content

Combining Wearable Technology to Crate Internet+Digital Hospital-remote Home Type 2 Diabetes Follow-up Management Mode

Combining Wearable Technology to Crate Internet+Digital Hospital-remote Home Type 2 Diabetes Follow-up Management Mode

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04973644
Enrollment
120
Registered
2021-07-22
Start date
2021-08-21
Completion date
2022-07-23
Last updated
2025-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Type 2

Brief summary

This study intends to combining wearable technology to crate Internet+Digital Hospital-remote Home Type 2 Diabetes follow-up management mode.To preliminarily explore compared with the traditional medical treatment mode, whether the new management mode of DM can improve the management objectives and patient satisfaction of T2DM and reduce medical costs. The study provides a powerful reference for establishing corresponding platforms and promoting such models at the government management level in the future.

Detailed description

Background:The prevalence of T2DM in Chinese adults has exceeded 10%, and the prevalence of abnormal glucose metabolism has exceeded 40% in people older than 18 years. This will lead to a significant increase in the prevalence of DM complications in the next decade, and the disability and death caused by complications will also seriously affect the quality of life of patients and bring a huge social and economic burden.This randomized controlled trial intends to combining wearable technology to crate Internet+Digital Hospital-remote Home T2DM follow-up management mode.To preliminarily explore compared with the traditional medical treatment mode, whether the new management mode of DM can improve the management objectives and patient satisfaction of T2DM and reduce medical costs. The study provides a powerful reference for establishing corresponding platforms and promoting such models at the government management level in the future. Methods:The study was a parallel-group, randomised, controlled trial. the number of cases planned to be included in 200 cases. Participants were randomly assigned to the intervention or control group.The intervention group receives Internet + Digital Hospital-remote home management mode,including remote monitoring devices+Internet management platform, dietary recommendations, exercise supervision, web education, information pushing, doctor-patient interaction, etc.The control group receives the traditional management mode, including routine dietary and exercise recommendations, education as well as monitor in the clinic.

Interventions

DEVICERemote monitoring devices+Internet management platform

Remote monitoring devices collects blood glucose, total cholesterol, serum ketones and serum uric acid,then upload data to the platform.

Sponsors

Second Affiliated Hospital of Nanchang University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed with type 2 diabetes according to the World Health Organization criteria; * Aged between 18 and 70 years; * Glycosylated haemoglobin (HbA1C%) between 7% and 9%.

Exclusion criteria

* Type 1 diabetes; * Gestational diabetes; * Other special types of diabetes; * Moderate-severe insufficiency of heart , liver, kidney and lung; * Complicated with acute disease or stress status.

Design outcomes

Primary

MeasureTime frameDescription
HbA1c concentrationBaseline, Week 12, Week 24HbA1c concentration reflects the average blood glucose level

Secondary

MeasureTime frameDescription
Fasting insulinBaseline, Week 24Insufficient insulin secretion or insulin resistance is a major cause of diabetes
Blood pressureBaseline, Week 24Normal systolic blood pressure \<140mm Hg, diastolic blood pressure\<90mmHg in China.
Total cholesterolBaseline, Week 24Total cholesterol refers to the sum of cholesterol contained by all lipoproteins in the blood.Normal Total cholesterol values \<5.17 mmol/L
TriglyceridesBaseline, Week 24Normal Triglycerides values Triglycerides\<1.7 mmol/L
LDL-CBaseline, Week 24The level of LDL-C is correlated with the incidence and severity of cardiovascular disease
HDL-CBaseline, Week 24The level of HDL-C is inversely associated with coronary heart disease.
FBGBaseline, Week 24Normal FBG values are 3.9 to 6.1 mmol/L
Waist circumferenceBaseline, Week 24Waist circumference is an important index to determine central obesity.
BMIBaseline, Week 24BMI is an internationally used measure of how fat and thin a person is and whether they are healthy or not.The calculation formula is: BMI= weight/height\^2.
Serum uric acidBaseline, Week 24Serum uric acid is the end product of purine catabolism.Is excreted by the kidney with urine.Serum uric acid measurement is a sensitive marker for the diagnosis of severe renal impairment.
Serum creatinineBaseline, Week 24Clinically detecting serum creatinine is one of the main methods to understand renal function, and it is an important indicator of kidney function, and an elevated serum creatinine means the damage of kidney function.
Urinary microalbumin / creatinine ratioBaseline, Week 24Urinary microalbumin /creatinine ratio is the test used clinically to judge microalbuminuria, examine early renal lesions, and is more commonly used clinically for early diabetic nephropathy.
Diabetes Treatment Satisfaction QuestionnaireWeek 24Comments on the distribution of treatment satisfaction scores measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ).There are 8 items in total, including three dimensions of treatment satisfaction, self-perceived hyperglycemia and self-perceived hypoglycemia.The minimum and maximum values are 0 and 36 ,respectively.Higher scores mean a better outcome.
WeightBaseline, Week 24Standard weight is one of the important signs to reflect and measure a person's health status

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026